Orphanet Journal of Rare Diseases (Apr 2011)

Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema

  • de Serres Frederick,
  • Lara Beatriz,
  • Blanco Ignacio

DOI
https://doi.org/10.1186/1750-1172-6-14
Journal volume & issue
Vol. 6, no. 1
p. 14

Abstract

Read online

Abstract Up to now alpha 1-antitrypsin (AAT) augmentation therapy has been approved only for commercial use in selected adults with severe AAT deficiency-related pulmonary emphysema (i.e. PI*ZZ genotypes as well as combinations of Z, rare and null alleles expressing AAT serum concentrations